Arexvy, the First RSV Vaccine for Older Adults, Granted Approval by HAS

Arexvy, the First RSV Vaccine for Older Adults, Granted Approval by HAS

By, Admin 17 May 2024

Overview

Arexvy, the world's first respiratory syncytial virus (RSV) vaccine, has recently gained approval from the Health Sciences Authority (HSA) of Singapore for immunizing individuals aged 60 years and above against lower respiratory tract disease (LRTD) caused by RSV. This groundbreaking achievement underscores GSK's commitment to safeguarding the health of older adults in Singapore by providing protection against a range of infectious diseases.

Words from GSK Singapore

  • Raakhi Sippy, Vice President & General Manager of GSK Singapore, expressed satisfaction in introducing this vaccine to over one million older adults in Singapore, highlighting the extensive research and development efforts involved. 
  • With a growing portfolio of adult vaccines, GSK aims to promote disease prevention and support healthier aging among Singapore's population.

RSV Infections: Impact

  • In 2019, RSV infections resulted in significant morbidity and mortality among individuals aged 60 and above globally, with millions of cases leading to hospitalizations and fatalities. 
  • Studies conducted in Singapore have revealed a considerable prevalence of RSV infections among older adults, emphasizing the need for preventive measures.

RSV

  • RSV is a contagious virus primarily affecting the respiratory system and often presenting symptoms similar to other respiratory infections. 
  • However, the impact of RSV can be particularly severe among individuals aged 60 and above, especially those with underlying medical conditions, leading to increased hospitalization rates and mortality.

AReSVi-006 Phase III trial

Clinical trial data from the AReSVi-006 Phase III trial demonstrated Arexvy's efficacy in preventing RSV-induced LRTD among older adults, with particularly promising results in those with underlying medical conditions.

RSV Infections in Older Adults

  • Dr. Stephanie Cinthu Stephen Ambrose, Country Medical Director at GSK Singapore, stressed the importance of protecting older adults from RSV infections, especially given Singapore's aging population trends. 
  • As the population ages, prioritizing preventive measures against infectious diseases like RSV becomes increasingly crucial to maintaining the health and well-being of older adults.

Arexvy with AS01E Adjuvant

  • Arexvy, GSK's RSV vaccine for older adults, combines a recombinant subunit prefusion RSV F glycoprotein antigen (RSVPreF3) with GSK's proprietary AS01E adjuvant. 
  • Approved in multiple countries, including Europe, Japan, the UK, Canada, and Australia, Arexvy has shown promise in preventing RSV-LRTD in individuals aged 60 and above.

AReSVi-006 Trial

  • The AReSVi-006 trial, conducted across 17 countries, aimed to demonstrate the efficacy of a single dose of GSK's RSV vaccine in individuals aged 60 and above, further validating its effectiveness in this vulnerable population.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!